CJC-1295 / Ipamorelin

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue that employs Drug Affinity Complex (DAC) technology to achieve covalent albumin binding in circulation, extending its biological half-life from minutes to approximately 6–8 days. This sustained presence enables continuous stimulation of pituitary somatotrophs and prolonged elevation of both growth hormone and IGF-1 levels in research models.

Ipamorelin is a pentapeptide growth hormone secretagogue receptor (GHS-R1a) agonist that triggers GH release through the ghrelin signaling pathway — mechanistically independent of GHRH. Its defining characteristic is selectivity: unlike earlier secretagogues such as GHRP-6, ipamorelin stimulates growth hormone release with minimal concomitant increases in cortisol, prolactin, or ACTH, producing a cleaner pharmacological profile.

The combination leverages convergent signaling on somatotroph cells — simultaneous GHRH receptor and ghrelin receptor activation produces synergistic GH pulse amplification exceeding either agent alone. ROEHN supplies this blend at 99% HPLC-verified purity (each component) as a co-lyophilized powder, supporting research into IGF-1 kinetics, body composition, sleep architecture, and recovery in aging and performance models.